KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $4.3 million.

  • Halozyme Therapeutics' Interest Expenses fell 503.98% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 million, marking a year-over-year decrease of 543.28%. This contributed to the annual value of $18.1 million for FY2024, which is 355.51% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Interest Expenses of $4.3 million as of Q3 2025, which was down 503.98% from $4.4 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Interest Expenses peaked at $7.5 million during Q3 2022, and registered a low of $1.8 million during Q2 2021.
  • Moreover, its 5-year median value for Interest Expenses was $4.5 million (2023), whereas its average is $3.9 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Interest Expenses crashed by 6498.8% in 2021, and later skyrocketed by 32839.22% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Interest Expenses (Quarter) stood at $2.1 million in 2021, then soared by 122.38% to $4.6 million in 2022, then increased by 14.22% to $5.2 million in 2023, then decreased by 13.03% to $4.5 million in 2024, then fell by 5.37% to $4.3 million in 2025.
  • Its Interest Expenses was $4.3 million in Q3 2025, compared to $4.4 million in Q2 2025 and $4.5 million in Q1 2025.